Courts and prosecutors have a frontline role to play in the fight against the opioid epidemic, but don’t expect high-ranked officials from Big Pharma to face criminal prosecution any time soon, a group of criminal justice officials from across the country said during a panel discussion March 16.

“I wouldn’t get anyone’s hopes up, There’s just a host of problems,” New York City’s Special Narcotics Prosecutor Bridget Brennan told the audience, adding that statute of limitations issues might be the biggest hurdle in prosecuting pharmaceutical executives.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]